Repositioning Candidate Details
| Candidate ID: | R1184 |
| Source ID: | DB08908 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Dimethyl fumarate |
| Synonyms: | (E)-But-2-enedioic acid dimethyl ester; 1,2-bis(methoxycarbonyl)-trans-ethylene; Dimethyl fumarate; Dimethyl trans-ethylenedicarboxylate; Fumaric acid, dimethyl ester; trans-1,2-Ethylenedicarboxylic acid dimethyl ester; trans-Butenedioic acid dimethyl ester |
| Molecular Formula: | C6H8O4 |
| SMILES: | [H]\C(=C(\[H])C(=O)OC)C(=O)OC |
| Structure: |
|
| DrugBank Description: | Dimethyl fumarate is an anti-inflammatory. It is indicated for multiple sclerosis patients with relapsing forms and is also being investigated for the treatment of psoriasis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera. |
| CAS Number: | 624-49-7 |
| Molecular Weight: | 144.1253 |
| DrugBank Indication: | Used in multiple sclerosis patients with relapsing forms. |
| DrugBank Pharmacology: | The physiological effects dimethyl fumarate has on the body is not well understood. It is known that dimethyl fumarate has anti-inflammatory and cytoprotective effects, which both are likely involved in its actions in multiple sclerosis patients. |
| DrugBank MoA: | The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF). MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. As well MMF is an agonist at the nicotinic acid receptor, but the relevance of this is not known. |
| Targets: | Kelch-like ECH-associated protein 1 binder; Transcription factor p65 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S04 | Anti-oxidative stress | oxidative stress | α-tocopherol: antioxidant | Vitamin E | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|